ITC

2024

1. CD137 (4-1BB) and T-Lymphocyte Exhaustion

   Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 3971-3973

2. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

   Nature Communications, Vol. 15, Núm. 1

3. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

   Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

4. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

   Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

5. Dendritic Cells in Cancer Immunology and Immunotherapy

   Cancers, Vol. 16, Núm. 5

6. Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy

   Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 16, pp. 3355-3357

7. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

   Clinical Genitourinary Cancer, Vol. 22, Núm. 5

8. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C

   Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

9. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

   Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

10. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

11. Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer

    Genes and Immunity

12. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

13. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers

    Journal for immunotherapy of cancer, Vol. 12, Núm. 9

14. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma

    OncoImmunology, Vol. 13, Núm. 1

15. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391

16. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

17. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

18. PARP inhibitors alone or in combination for prostate cancer

    Therapeutic Advances in Urology, Vol. 16

19. Regional and intratumoral adoptive T-cell therapy

    Immuno-Oncology and Technology, Vol. 24

20. Reply to the Letter to the Editor “Reflections on the statistical methodology in nivolumab and ipilimumab therapy research” by S. Yang

    Annals of Oncology